Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
Author(s)DuPage, Michel J.; Brauneis, Alison L.; Jacks, Tyler E.
MetadataShow full item record
The development of animal models of lung cancer is critical to our understanding and treatment of the human disease. Conditional mouse models provide new opportunities for testing novel chemopreventatives, therapeutics and screening methods that are not possible with cultured cell lines or xenograft models. This protocol describes how to initiate tumors in two conditional genetic models of human non-small cell lung cancer (NSCLC) using the activation of oncogenic K-ras alone or in combination with the loss of function of p53. We discuss methods for sporadic expression of Cre in the lungs through engineered adenovirus or lentivirus, and provide a detailed protocol for the administration of the virus by intranasal inhalation or intratracheal intubation. The protocol requires 1–5 min per mouse with an additional 30–45 min to set-up and allow for the recovery of mice from anesthesia. Mice may be analyzed for tumor formation and progression starting 2–3 weeks after infection.
Departmentmove to dc.description.sponsorship; Koch Institute for Integrative Cancer Research at MIT
Nature Publishing Group
DuPage, Michel, Alison L Dooley, and Tyler Jacks. “Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.” Nature Protocols 4, no. 8 (June 25, 2009): 1064-1072.
Author's final manuscript